Skip to main content

Advertisement

Fig. 3 | Cell & Bioscience

Fig. 3

From: TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2

Fig. 3

TUG1 epigenetically silenced PDCD4 expression by recruiting EZH2 in ESCC cells. a Pearson correlation analysis between TUG1 and EZH2 in 195 tumor tissue samples of ESCC from TCGA. b TUG1 subcellular location was explored in EC9706/DDP cells. GAPDH acted as a cytoplasm control and U6 used as a nucleus control. c PDCD4 protein levels in ECA109/DDP cells transfected with si-con or si-TUG1. d EZH2 and PDCD4 protein levels in ECA109/DDP cells transfected with si-con or si-EZH2. e RNA pull-down assay indicated the binding of TUG1 with EZH2. f RIP assay was performed in ECA109/DDP cells and the co-precipitated RNA was subjected to qRT-PCR for TUG1. g qRT-PCR analysis following ChIP was performed to evaluate the enrichment of EZH2 and H3K27me3 on the PDCD4 promoter in ECA109/DDP cells. h Luciferase reporter assay was performed to evaluate the activity of the PDCD4 promoter in ECA109/DDP cells transfected with (si-con or si-TUG1) or (Vector or PDCD4). i The correlation analysis between TUG1 and PDCD4 expression in ESCC tumor specimen. *P < 0.05

Back to article page